DK564989D0 - Bindingsproteiner - Google Patents

Bindingsproteiner

Info

Publication number
DK564989D0
DK564989D0 DK564989A DK564989A DK564989D0 DK 564989 D0 DK564989 D0 DK 564989D0 DK 564989 A DK564989 A DK 564989A DK 564989 A DK564989 A DK 564989A DK 564989 D0 DK564989 D0 DK 564989D0
Authority
DK
Denmark
Prior art keywords
binding protein
somatomedins
insulin
bind
producing
Prior art date
Application number
DK564989A
Other languages
English (en)
Other versions
DK564989A (da
Inventor
Christopher Binkert
Guenther F Heinrich
Juerg Schwander
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of DK564989D0 publication Critical patent/DK564989D0/da
Publication of DK564989A publication Critical patent/DK564989A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK564989A 1988-11-11 1989-11-10 Bindingsproteiner DK564989A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888826451A GB8826451D0 (en) 1988-11-11 1988-11-11 Improvements in/relating to organic compounds

Publications (2)

Publication Number Publication Date
DK564989D0 true DK564989D0 (da) 1989-11-10
DK564989A DK564989A (da) 1990-05-12

Family

ID=10646720

Family Applications (1)

Application Number Title Priority Date Filing Date
DK564989A DK564989A (da) 1988-11-11 1989-11-10 Bindingsproteiner

Country Status (16)

Country Link
EP (1) EP0369943B1 (da)
JP (1) JPH0341096A (da)
AT (1) ATE112311T1 (da)
AU (1) AU623447B2 (da)
CA (1) CA2002609A1 (da)
DE (1) DE68918556D1 (da)
DK (1) DK564989A (da)
FI (1) FI895346A7 (da)
GB (1) GB8826451D0 (da)
HU (2) HU895607D0 (da)
IL (1) IL92257A0 (da)
MY (1) MY104673A (da)
NZ (1) NZ231333A (da)
PL (1) PL162290B1 (da)
PT (1) PT92278B (da)
ZA (1) ZA898610B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
CA2090705A1 (en) * 1990-08-28 1992-03-01 Michael C. Kiefer Genetic material encoding igfbp-5
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
JPH06503711A (ja) * 1990-08-28 1994-04-28 カイロン　コーポレイション 新規インシュリン様成長因子結合タンパク質（ｉｇｆｂｐ―４）
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
WO1992012243A1 (en) * 1991-01-08 1992-07-23 Chiron Corporation New insulin-like growth factor binding protein (igfbp-6)
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
CN1134111A (zh) * 1993-04-07 1996-10-23 赛纳根公司 使用胰岛素样生长因子结合蛋白质的方法
ATE226958T1 (de) * 1993-09-20 2002-11-15 Celtrix Pharma Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
SE9303784D0 (sv) * 1993-11-16 1993-11-16 Kabi Pharmacia Ab Igf
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
ES2329220T3 (es) 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
CA2439735A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
DK2274978T3 (da) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Fremgangsmåder til behandling af en insulin-lignende vækstfaktor-I(IGF-I)-mangel
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
CA2678008C (en) 2005-06-17 2013-07-30 Imclone Systems Incorporated Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
AU2007212447B2 (en) 2006-02-03 2013-02-21 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
EP3681602B1 (en) 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
KR20230113287A (ko) 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
US20250099541A1 (en) 2022-01-19 2025-03-27 Oak Hill Bio Ltd Compositions and methods for reducing oxidation of igf-1/igfbp
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
JP2026504910A (ja) 2023-02-14 2026-02-10 オーク ヒル バイオ リミテッド Ｇｉ組織における調節不全を治癒する処置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
ATE132164T1 (de) * 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors

Also Published As

Publication number Publication date
CA2002609A1 (en) 1990-05-11
GB8826451D0 (en) 1988-12-14
PT92278B (pt) 1995-09-12
EP0369943B1 (en) 1994-09-28
DE68918556D1 (de) 1994-11-03
ZA898610B (en) 1991-07-31
FI895346A7 (fi) 1990-05-12
HU895607D0 (en) 1990-01-28
HUT53936A (en) 1990-12-28
PT92278A (pt) 1990-05-31
DK564989A (da) 1990-05-12
AU623447B2 (en) 1992-05-14
MY104673A (en) 1994-05-31
NZ231333A (en) 1992-10-28
AU4453689A (en) 1990-06-07
PL162290B1 (pl) 1993-09-30
ATE112311T1 (de) 1994-10-15
IL92257A0 (en) 1990-07-26
JPH0341096A (ja) 1991-02-21
EP0369943A1 (en) 1990-05-23
FI895346A0 (fi) 1989-11-09
HU895836D0 (en) 1990-01-28

Similar Documents

Publication Publication Date Title
DK564989A (da) Bindingsproteiner
AU630950B2 (en) Fibronectin binding protein as well as its preparation
US5043429B1 (en) Protein fragments containing factor VIII binding domain of von willebrand factor
DK0526452T4 (da) Hybridimmunoglobuliner
NO885326L (no) Human vevfaktor-beslektede dna-segmenter, polypeptider ogantistoffer.
IL85983A0 (en) Human somatomedin carrier protein subunits and process for producing them
EP0295645A3 (en) Method for purifying factor viii:c, von willebrand factor and complexes thereof
CA2006322A1 (en) Recombinant dna molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
SE8702272D0 (sv) A fibrnectin binding protein as well as its preparation
ES552431A0 (es) Procedimiento para preparar plasmidos de expresion prhw11 y prhw12
HUT64369A (en) Collagen binding protein and method for producing it
HUT53125A (en) Process for producing peptides with anticoagulant activity
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
DE59309978D1 (de) Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
FI891652A7 (fi) Menetelmä proteiinien valmistamiseksi, joiden N-terminaali alkaa proliinilla
ZA903843B (en) Tumor necrosis factor binding protein ii,its purification and antibodies thereto

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment